Everest Medicines (01952) rose over 3%, reaching 3.45% higher at HK$26.42 as of press time, with a turnover of HK$85.8234 million.
On the news front, on November 14, Everest Medicines' Velsipity® (etrasimod arginine tablets) and Xerava® (eravacycline hydrochloride for injection) passed the national medical insurance negotiation and were included for the first time in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2026)", with the new catalog set to take effect officially on January 1, 2027.
At the same time, its IgA nephropathy causative treatment drug Nefecon® (budesonide enteric-coated capsules) successfully renewed its contract and remains in the catalog.
With this, Everest Medicines now has three products entered into the national medical insurance catalog, covering areas such as ulcerative colitis, complicated intra-abdominal infections, and IgA nephropathy, among which Velsipity® achieved medical insurance inclusion in its first year on the market.
It is reported that Velsipity® is China's first and only approved sphingosine-1-phosphate (S1P) receptor modulator for the treatment of UC. In the largest Asian multicenter Phase III clinical study (ENLIGHT UC) conducted to date for patients with moderate-to-severe UC, Velsipity® achieved a 52-week mucosal healing rate of 51.9%, and long-term follow-up showed favorable medication safety.
Comments